Paper24676741
Vancomycin: the tale of the vanquisher and the pyrrhic victory.
De Vriese AS and 1 other. Perit Dial Int, 2014. Cited by 11 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Vancomycin: the tale of the vanquisher and the pyrrhic victory. Papers, record 24676741. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24676741
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Methicillin-Resistant Staphylococcus aureus | Major topic |
| Staphylococcal Infections | Major topic |
| Staphylococcus aureus | Major topic |
| Vancomycin | Major topic |
| Vancomycin Resistance | Major topic |
| Humans | |
| Risk Factors |
Source PubMed
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15,184,410 | Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. | J Clin Microbiol | 2004 | https://conductscience.org/library/papers/15184410 | PubMed |
| 2 | 20,628,102 | Peritoneal dialysis-related infections recommendations: 2010 update. | Perit Dial Int | 2010 | https://conductscience.org/library/papers/20628102 | PubMed |
| 3 | 19,635,961 | Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. | Antimicrob Agents Chemother | 2009 | https://conductscience.org/library/papers/19635961 | PubMed |
| 4 | 23,567,819 | The evolution of vancomycin intermediate Staphylococcus aureus (VISA) and heterogenous-VISA. | Infect Genet Evol | 2014 | https://conductscience.org/library/papers/23567819 | PubMed |
| 5 | 22,302,374 | The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. | Clin Infect Dis | 2012 | https://conductscience.org/library/papers/22302374 | PubMed |
| 6 | 19,586,413 | Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. | Clin Infect Dis | 2009 | https://conductscience.org/library/papers/19586413 | PubMed |
| 7 | 23,165,462 | Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. | Antimicrob Agents Chemother | 2013 | https://conductscience.org/library/papers/23165462 | PubMed |
| 8 | 21,109,164 | VRSA-doomsday superbug or damp squib? | Lancet Infect Dis | 2010 | https://conductscience.org/library/papers/21109164 | PubMed |
| 9 | 21,540,106 | Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis. | Eur J Pharm Sci | 2011 | https://conductscience.org/library/papers/21540106 | PubMed |
| 10 | 22,284,995 | Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP Database. | Clin Ther | 2012 | https://conductscience.org/library/papers/22284995 | PubMed |
| 11 | 9,249,217 | Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | J Antimicrob Chemother | 1997 | https://conductscience.org/library/papers/9249217 | PubMed |
| 12 | 15,462,252 | Vancomycin dosing in high flux hemodialysis: a limited-sampling algorithm. | Am J Health Syst Pharm | 2004 | https://conductscience.org/library/papers/15462252 | PubMed |
| 13 | 17,369,615 | Single UK centre experience on the treatment of PD peritonitis--antibiotic levels and outcomes. | Nephrol Dial Transplant | 2007 | https://conductscience.org/library/papers/17369615 | PubMed |
| 14 | 2,354,591 | Clearance from dialysate and equilibration of intraperitoneal vancomycin in continuous ambulatory peritoneal dialysis. | Clin Pharmacokinet | 1990 | https://conductscience.org/library/papers/2354591 | PubMed |
| 15 | 14,506,006 | Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods. | Antimicrob Agents Chemother | 2003 | https://conductscience.org/library/papers/14506006 | PubMed |
| 16 | 19,164,246 | Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. | Perit Dial Int | 2009 | https://conductscience.org/library/papers/19164246 | PubMed |
| 17 | 15,561,842 | Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. | Antimicrob Agents Chemother | 2004 | https://conductscience.org/library/papers/15561842 | PubMed |
| 18 | 24,047,554 | In vivo evolution of antimicrobial resistance in a series of Staphylococcus aureus patient isolates: the entire picture or a cautionary tale? | J Antimicrob Chemother | 2014 | https://conductscience.org/library/papers/24047554 | PubMed |
| 19 | 9,890,319 | Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis. The Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS). | J Am Soc Nephrol | 1999 | https://conductscience.org/library/papers/9890319 | PubMed |
| 20 | 19,590,063 | Staphylococcus aureus infections in hemodialysis: what a nephrologist should know. | Clin J Am Soc Nephrol | 2009 | https://conductscience.org/library/papers/19590063 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38,106,569 | The Association Between Serum Vancomycin Level and Clinical Outcome in Patients With Peritoneal Dialysis Associated Peritonitis. | Kidney Int Rep | 2023 | https://conductscience.org/library/papers/38106569 | PubMed |
| 32,065,053 | Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy. | Perit Dial Int | 2020 | https://conductscience.org/library/papers/32065053 | PubMed |
| 28,836,582 | Influences of renal function descriptors on population pharmacokinetic modeling of vancomycin in Chinese adult patients. | Acta Pharmacol Sin | 2018 | https://conductscience.org/library/papers/28836582 | PubMed |
| 27,840,751 | Systemic Toxicity of Intraperitoneal Vancomycin. | Case Rep Nephrol | 2016 | https://conductscience.org/library/papers/27840751 | PubMed |
| 26,711,763 | Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure. | Antimicrob Agents Chemother | 2015 | https://conductscience.org/library/papers/26711763 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24676741
GET https://conductscience.org/api/papers/v1/24676741/references?page=2